Epstein Files Search

EFTA00703494Set 9

2013-07-302p647w

IMDx has achieved a pivotal milestone with the receipt of FDA clearance for its Vancomycin Resistance (VanR) test for the Abbott m2000 system. This test detects vancomycin-resistance genes that ... associated with vancomycin resistant enterococci (VRE.) VRE are bacteria which have become resistant to the antibiotic vancomycin, and are responsible for a variety of healthcare- associated infections, including surgical wound ... that detects the presence of vanA and vanB genes that can be associated with vancomycin-resistant enterococci (VRE). This is one of the tests in IMDx's portfolio of infectious

https://www.justice.gov/epstein/files/DataSet%209/EFTA00703494.pdf

EFTA00920661Set 9

2011-09-282p619w

care infections, the IMDI" VanR for Abbott m2000' test (see below). This test detects vancomycin-resistance genes associated with vancomycin resistant enterococci (VRE.) Enterococci are normally found in the GI/GU ... Alice IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant Enterococci Cambridge, MA, September ... test accurately detects and distinguishes the vanA and vanB genes most commonly found in vancomycin-resistant enterococci (VRE) in specimens from patients at risk for colonization or infection. Detection

https://www.justice.gov/epstein/files/DataSet%209/EFTA00920661.pdf

EFTA00920674Set 9

2011-09-282p672w

care infections, the IMDxm VanR for Abbott m2000' test (see below). This test detects vancomycin-resistance genes associated with vancomycin resistant enterococci (VRE.) Enterococci are normally found in the GI/GU ... Alice IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant Enterococci Cambridge, MA, September ... test accurately detects and distinguishes the vanA and vanB genes most commonly found in vancomycin-resistant enterococci (VRE) in specimens from patients at risk for colonization or infection. Detection

https://www.justice.gov/epstein/files/DataSet%209/EFTA00920674.pdf

EFTA00662732Set 9

2014-05-082p680w

VanR QS-RGQ Kit is intended as an aid to identify, prevent, and control vancomycin-resistant colonization in patients at risk for vancomycin-resistant enterococci infection. A Premarket Notification

https://www.justice.gov/epstein/files/DataSet%209/EFTA00662732.pdf

EFTA00605649Set 9

2p445w

VanR QS-RGQ Kit is intended as an aid to identify, prevent, and control vancomycin-resistant colonization in patients at risk for vancomycin-resistant enterococci infection. A Premarket Notification

https://www.justice.gov/epstein/files/DataSet%209/EFTA00605649.pdf

EFTA00730018Set 9

21p6,610w

Control Detects most commonly encountered resistance markers for infections, including mecA (methicillin resistance), vanA/vanB (vancomycin resistance) and Clostridium difficile (C. dill.) toxA/toxB genes. Currently, the incidence of hospital acquired infections

https://www.justice.gov/epstein/files/DataSet%209/EFTA00730018.pdf

EFTA00765781Set 9

21p6,612w

Control Detects most commonly encountered resistance markers for infections, including mecA (methicillin resistance), vanA/vanB (vancomycin resistance) and Clostridium difficile (C. dill.) toxA/toxB genes. Currently, the incidence of hospital acquired infections

https://www.justice.gov/epstein/files/DataSet%209/EFTA00765781.pdf

EFTA00934705Set 9

2012-05-152p629w

infectious disease testing portfolio, which includes tests hospital-acquired infections including C. difficile and vancomycin-resistant enterococci. My best, Alice IntelligentMDx Announces CE-Marking of a new high-throughput test ... Abbott m2000 system includes real-time PCR assays for the detection of vancomycin-resistant enterococci (VRE) and toxigenic C. difficile. *The IMDx GBS for Abbott m2000 assay is CE-marked

https://www.justice.gov/epstein/files/DataSet%209/EFTA00934705.pdf

EFTA00718974Set 9

2012-03-132p705w

Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium dinette, and vancomycin-resistant enterococci. Diagnostic tests for Group B streptococcus and Influenza MB and RSV are scheduled

https://www.justice.gov/epstein/files/DataSet%209/EFTA00718974.pdf

EFTA00930939Set 9

2012-03-133p654w

Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium dinette, and vancomycin-resistant enterococci. Diagnostic tests for Group B streptococcus and Influenza MB and RSV are scheduled

https://www.justice.gov/epstein/files/DataSet%209/EFTA00930939.pdf

EFTA00671769Set 9

2012-07-301p210w

disease testing portfolio, which includes tests for hospital-acquired infections including C. difficile and vancomycin-resistant enterococci and prenatal screening of Group B Streptococcus. My best, Alice Alice A. Jacobs

https://www.justice.gov/epstein/files/DataSet%209/EFTA00671769.pdf

EFTA00614609Set 9

2011-01-201p379w

silico verified. Tests will include identification of the following infectious organisms. Clostridium difficile, Vancomycin-Resistance Enterococci (VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus

https://www.justice.gov/epstein/files/DataSet%209/EFTA00614609.pdf

EFTA00902109Set 9

2011-01-213p622w

silico verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin- Resistance Enterococci (VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus

https://www.justice.gov/epstein/files/DataSet%209/EFTA00902109.pdf

EFTA00924754Set 9

2011-11-303p932w

Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium difficile, and vancomycin-resistant enterococci. The IMDx pipeline includes a range of infectious disease assays, a subset of which

https://www.justice.gov/epstein/files/DataSet%209/EFTA00924754.pdf

EFTA00640072Set 9

2011-01-202p505w

silica verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin-Resistance Enterococci (VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus

https://www.justice.gov/epstein/files/DataSet%209/EFTA00640072.pdf

EFTA00648481Set 9

2011-01-212p669w

silica verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin-Resistance Enterococci (VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus

https://www.justice.gov/epstein/files/DataSet%209/EFTA00648481.pdf

EFTA00719780Set 9

2011-11-292p812w

Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium difficile, and vancomycin-resistant enterococci. The IMDx pipeline includes a range of infectious disease assays, a subset of which

https://www.justice.gov/epstein/files/DataSet%209/EFTA00719780.pdf